TB
This company develops science-driven therapeutics aimed at aggressive human cancers. They focus on creating transformative medicines by coupling drug development with biomarker identification. This approach ensures their novel drugs are targeted toward the patient populations most likely to benefit.
Updated 20 months ago
Funding
$120K raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Funding rounds are not available yet.
Founders
Product
Features
- This company develops science-driven therapeutics aimed at aggressive human cancers. They focus on creating transformative medicines by coupling drug development with biomarker identification. This approach ensures their novel drugs are targeted toward the patient populations most likely to benefit.